| Literature DB >> 30991717 |
Elodie Clain1, Juliano G Haddad2, Andrea C Koishi3, Laura Sinigaglia4,5, Walid Rachidi6, Philippe Desprès7, Claudia N Duarte Dos Santos8, Pascale Guiraud9, Nolwenn Jouvenet10, Chaker El Kalamouni11.
Abstract
The recent emergence and re-emergence of viral infections transmitted by vectors, such as the Zika virus (ZIKV) and Dengue virus (DENV), is a cause for international concern. These highly pathogenic arboviruses represent a serious health burden in tropical and subtropical areas of the world. Despite the high morbidity and mortality associated with these viral infections, antiviral therapies are missing. Medicinal plants have been widely used to treat various infectious diseases since millenaries. Several compounds extracted from plants exhibit potent effects against viruses in vitro, calling for further investigations regarding their efficacy as antiviral drugs. Here, we demonstrate that an extract from Psiloxylon mauritianum, an endemic medicinal plant from Reunion Island, inhibits the infection of ZIKV in vitro without exhibiting cytotoxic effects. The extract was active against different ZIKV African and Asian strains, including an epidemic one. Time-of-drug-addition assays revealed that the P. mauritianum extract interfered with the attachment of the viral particles to the host cells. Importantly, the P. mauritianum extract was also able to prevent the infection of human cells by four dengue virus serotypes. Due to its potency and ability to target ZIKV and DENV particles, P. mauritianum may be of value for identifying and characterizing antiviral compounds to fight medically-important flaviviruses.Entities:
Keywords: Dengue virus; Psiloxylon mauritianum; Zika virus; antiviral activity; natural compounds; nutraceuticals
Mesh:
Substances:
Year: 2019 PMID: 30991717 PMCID: PMC6515236 DOI: 10.3390/ijms20081860
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The cytotoxicity and genotoxicity of the P. mauritianum extract on mammalian cells. (A) Vero and A549 cells were incubated with different concentrations of the P. mauritianum extract for 24 h. The cell viability was determined using the metabolic activity by an MTT assay. (B) Human primary keratinocytes (HKPM) and fibroblasts (FMa) were treated with an increased concentration of the P. mauritianum extract for 24 h, and their viability was evaluated by an MTT assay. (A,B) The results are the means ± SD of three independent experiments and are expressed as the relative value compared to untreated cells. (C) Human cells (A549, HKPM and FMa) were treated 24 h with 100 µg mL−1 of the P. mauritianum extract. The cells were treated 10 min with H2O2 (50 µM) as a positive control. The genotoxicity was determined by observation of DNA degradation using a COMET assay visualized by Gel Red. The images are representative of three independent experiments. Scale bars are 50 µm. (D) The quantification of the COMET signal from the experiments represented in the images by using a COMET assay IV software. The results are means ± SD of three independent experiments and are expressed as the percentage of the tail intensity. A one-way ANOVA and Dunnett’s test for multiple comparisons were used for the statistical analysis (*** p < 0.001).
Figure 2P. mauritianum extract inhibits ZIKV attachment to the cell surface. (A) Schematic representation of time-of-drug-addition assays used to characterize the antiviral activity of the P. mauritianum extract (100 µg mL−1). Green arrow indicates the presence of the plant extract. (B) Flow cytometric analysis of GFP expression in Vero cells infected with ZIKVGFP during 24 h at MOI of 1 under the different experimental conditions shown in (A). The results are means ± SD of three independent experiments and are expressed as the relative value compared to untreated infected cells. (C) Virus binding assays: Vero cells were infected with ZIKV-MR766 at MOI of 1 for 1 h at 4 °C with or without 100 µg mL−1 of the P. mauritianum extract. EGCG (100 µM) were used as a positive control. The number of virus particles bound to the cell surface was measured by RT-qPCR. The values represent the mean ± SD of three independent experiments. (D) Viral inactivation assays: Vero cells were infected with ZIKVGFP pre-incubated during 1 h at 37 °C with four different concentration of P. mauritianum extract. A flow cytometric analysis of GFP fluorescence was performed 24 hp.i. The results shown are means ± SD of three independent experiments and are expressed as the relative value compared to untreated infected cells. Statistical analyses were performed using a one-way ANOVA and Dunnett’s test for multiple comparisons (*** p < 0.001; **** p < 0.0001; n.s = not significant).
Figure 3P. mauritianum extract inhibits the production of ZIKV ssRNA. ZIKV-MR766 particles were incubated with the P. mauritianum extract for 1 h at 37 °C. The EGCG treatment (100 µM) was used as positive control. Vero cells were left uninfected or were infected at an MOI of 1 for 24 h. (A) Cells were processed for FISH using a probe specific for viral RNA (red) and then stained with NucBlue to visualize the nuclei (blue). Cell membranes were stained with AF488-conjugated wheat germ agglutinin. Images are representative of three independent experiments. Scale bars are 20 μm. (B) Quantification of ZIKV ssRNA spots counted per field (fields contained on average 300 cells) from the experiments represented in the images. Data are means ± SD of three independent experiments. Statistical analyses were performed using a one-way ANOVA and Dunnett’s test for multiple comparisons (**** p < 0.0001).
Figure 4Antiviral activity of the P. mauritianum extract against the African and Asian ZIKV lineages. ZIKV-MR766 or ZIKV-PF13 were incubated with the P. mauritianum extract for 1 h at 37 °C. EGCG (100 µM) was used as a positive control. The Vero cells were infected at a MOI of 1 for 24 h. (A) The cells were processed for an immunofluorescence assay. The ZIKV E protein (red) and nuclei (blue) were visualized by fluorescence microscopy. The images are representatives of three independent experiments. Scale bars are 50 µm. The quantification of the number of (B) ZIKV-MR766 and (C) ZIKV-PF13 infected Vero cells from the experiments are represented in the images. The results shown are the means ± SD of three independent experiments. Statistical analyses were performed using a one-way ANOVA and Dunnett’s test for multiple comparisons (**** p < 0.0001).
Figure 5The P. mauritianum extract reduces the viral progeny production of the African and Asian ZIKV lineages. (A) ZIKV-MR766 or (B) ZIKV-PF13 were incubated with different concentrations of the P. mauritianum extract for 1 h at 37 °C. The Vero cells were infected at a MOI of 1 for 24 h. The release of infectious viral particles was measured by plaque forming assays. The results shown are the means ± SD of three independent experiments. Statistical analyses were performed using a one-way ANOVA and Dunnett’s test for multiple comparisons (** p < 0.01; *** p < 0.001).
Figure 6The P. mauritianum extract inhibits the infection of four DENV clinical isolates representative of the four serotypes. Four DENV serotypes (DENV-1, 2, 3 and 4) were pre-incubated with the P. mauritianum extract for 1 h at 37 °C. (A) Huh7.5 cells were infected for 48 h with DENV at the different MOI 0.2, 2, 0.5 and 2 for DENV 1–4, respectively. Recombinant IFN-α 2A (200 IU mL−1) was added 2 h post-infection and used as a positive control. The percentage of E positive cells was evaluated using the Operetta High-Content Imaging System (PerkinElmer). The results are the means ± SD of three independent experiments. (B) The residual infectious particles were titrated in C6/36 cells using a foci-forming immunodetection assay. The data represent the means ± SD from three independent experiments. A one-way ANOVA and Dunnett’s test for multiple comparisons were used for the statistical analysis (** p < 0.01; *** p < 0.001; **** p < 0.0001).